What are you looking for?
Need help finding what you are looking for? Contact Us

PUBLISHER: Knowledge Sourcing Intelligence | PRODUCT CODE: 1425123

Cover Image

PUBLISHER: Knowledge Sourcing Intelligence | PRODUCT CODE: 1425123

Endometriosis Treatment Market - Forecasts from 2024 to 2029

PAGES: 143 Pages
DELIVERY TIME: 1-2 business days
PDF (Single User License)
USD 4250
PDF (Multiple User License)
USD 4850
PDF (Enterprise License)
USD 7250

Add to Cart

The endometriosis treatment market is expected to grow at a CAGR of 11.87% from US$1.431 billion in 2022 to US$2.91 billion in 2029.

A common yet excruciating condition that can interfere with individuals' everyday lives is endometriosis. When endometriosis is present, tissue that resembles the uterine lining grows in additional places in one's pelvis and abdomen. Endometriosis can cause painful, prolonged periods in addition to reproductive issues. Medication or surgery is often used to treat endometriosis.

Growing prevalence of endometriosis

According to the World Health Organization, approximately 10% (190 million) of women and adolescents of reproductive age worldwide suffer from endometriosis. Extreme pelvic discomfort is a common side effect of endometriosis, particularly during menstruation. Some also experience pain when using the restroom or having intercourse. A few individuals struggle with conception. Regardless of their social standing or cultural background, endometriosis is a complicated illness that affects a large number of women worldwide from the time of their menarche until menopause. Endometriosis therapy often focuses on managing symptoms because there is presently no recognized cure for the condition. This has led to the growth of the endometriosis treatment industry.

Rising endometriosis awareness programs

Various government association is focusing on building programs to provide people with the required knowledge about endometriosis. For instance, The ENPOWR Project is EndoFound's youth-focused effort to provide menstrual health information and endometriosis education to teenagers in grades 9 through 12. Young women's understanding of endometriosis and dysmenorrhea can be improved by education. The campaign encouraged nursing and medical students to seek care for endometriosis early identification and management boosting the endometriosis treatment market. The Teen Outreach Programme is one of the Endometriosis Association's most significant educational programs because it focuses on teenage girls who are the disease's most susceptible victims and can significantly lessen the disease's effects on their lives. The association has given out 2,577 Teen Outreach instructional kits to thousands of children throughout 34 states.

Growth of Gonadotropin-Releasing Hormone (GnRH)

Gonadotropin-releasing hormone (GnRH) is used by the pituitary gland in the endocrine system to promote the synthesis of follicle-stimulating hormone and luteinizing hormone. The sex hormones testosterone, estrogen, and progesterone are produced by these gonadotropins (hormones). Sexual development, sex drive, and fertility depend on GnRH. GnRH indirectly promotes the body's synthesis of progesterone and estrogen in the female reproductive system. These are the main female sex hormones, and they are essential for conception and ovulation.

Artificial Intelligence and Telemedicine in the Treatment of Endometriosis

Communication and computer-based technologies have been successfully applied to healthcare administration in recent decades. Additionally, during the COVID-19 epidemic 2, these technologies were widely used in regular practice, particularly for the management of patients with persistent illnesses like endometriosis. Most endometriosis patients seeking treatment for pain alleviation or infertility were unable to visit hospitals due to pandemic limitations. The possibility of acute endometriosis problems such as intestinal blockage, rectal or urinary bleeding, cyst rupture, and excruciating abdominal pain was raised by this circumstance.

In North America, it is projected that the endometriosis treatment market will grow steadily.

The endometriosis treatment market in North America is anticipated to be fueled by the growing prevalence of endometriosis in the region. For instance, according to the Office on Women's Health, when tissue that resembles the lining within the uterus or womb grows outside of those organs it might lead to endometriosis. Endometriosis growths may swell and bleed throughout the menstrual period. It may affect more than 11 percent of American women between the ages of 15 and 44. It is more common in women in their 30s and 40s and may make getting pregnant more challenging. The symptoms may be controlled with a variety of treatments, which can also increase one's chances of getting pregnant.

Endometriosis Hormone Therapy

  • Progestin Therapy, Numerous progestin treatments, such as an intrauterine device with levonorgestrel (Mirena, Skyla), a contraceptive implant (Nexplanon), an intravenous contraceptive (Depo-Provera), or a progestin pill (Camila).
  • Aromatase Inhibitors, a group of medications known as aromatase inhibitors work to lower the level of estrogen in the body. To manage endometriosis, the doctor may advise using a combination hormonal contraception that combines an aromatase inhibitor with a progestin.
  • Hormonal Contraceptives, Birth control pills, patches, and vaginal rings assist regulate the hormones that cause the monthly accumulation of endometrial tissue. In some circumstances, using hormonal contraceptives, particularly continuous-cycle regimens, may lessen or eliminate discomfort.

FDA Approvals for Endometriosis Treatment Drugs

  • In June 2023, the supplemental Biologics Licence Application (sBLA) for Jemperli (dostarlimab) in combination with chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer was accepted by the US Food and Drug Administration (FDA), according to GSK plc.
  • In August 2022, Myovant Sciences and Pfizer Inc. announced that MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) has been approved by the U.S. Food and Drug Administration (FDA) as a once-daily, one-pill treatment for the management of moderate to severe endometriosis-related pain in premenopausal women. The treatment regimen may last up to 24 months.

Market Key Developments

  • In February 2022, to commercialize and market Linzagolix, an oral GnRH antagonist, ObsEva SA, a biopharmaceutical business researching and commercializing innovative medicines for women's health, and Theramex, a top global pharmaceutical firm specializing in women's health, have entered into a licensing agreement.
  • In November 2021, Organon and Forendo Pharma announced that they had signed a legally binding agreement under which Organon would acquire Forendo, a clinical-stage pharmaceutical firm that specializes in cutting-edge therapies for women's health.


By Treatment Type

  • Pain Medication
  • Hormone Therapy

By Drug Class

  • NSAIDs
  • Oral Contraceptive
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others
Product Code: KSI061616242



  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline


  • 2.1. Research Data
  • 2.2. Assumptions


  • 3.1. Research Highlights


  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis


  • 5.1. Introduction
  • 5.2. Pain Medication
  • 5.3. Hormone Therapy


  • 6.1. Introduction
  • 6.2. NSAIDs
  • 6.3. Oral Contraceptive
  • 6.4. Others


  • 7.1. Introduction
  • 7.2. Hospital Pharmacy
  • 7.3. Retail Pharmacy
  • 7.4. Others


  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others


  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix


  • 10.1. Bayer
  • 10.2. Apollo Cradle
  • 10.3. Endodiag
  • 10.4. HCA Healthcare UK
  • 10.5. EndoFound
  • 10.6. The Endometriosis Clinic
  • 10.7. The Endo Co
  • 10.8. Bupa
  • 10.9. NYU Langone Health
  • 10.10. Cromwell Hospital
Have a question?

Jeroen Van Heghe

Manager - EMEA



Christine Sirois

Manager - Americas


Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!